Anticoagulation in neonates and children: Pitfalls and dilemmas

Blood Reviews

Volumn 24, Issue 4-5, 2010, Pages 151-162

  Monagle, Paul ^a,b,c   Newall, Fiona ^a,b,c   Campbell, Janine ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Anticoagulation; Children; Low molecular weight heparins; Neonates; Unfractionated heparin; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN; WARFARIN;

ANAPHYLAXIS; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; BONE DENSITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOMYOPATHY; CHILD; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; FULMINATING PURPURA; HAIR LOSS; HEART VALVE REPLACEMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; MONITORING; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEWBORN; OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SIDE EFFECT; THROMBOSIS; TRACHEA CALCIFICATION; UREMIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHILD; HUMANS; INFANT; INFANT, NEWBORN;

EID: 77955469544     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.06.003     Document Type: Article

References (112)

1. Andrew M., Brooker L., Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994, 5(Suppl 1):S24-S36. discussion S59-64.
2. Schmidt B., Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995, 96(5 Pt 1):939-943.
3. Nowak-Gottl U., Dubbers A., Kececioglu D., Koch H.G., Kotthoff S., Runde J., et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: A prospective study. J Pediatr 1997, 131(4):608-612.
4. Baird C.W., Zurakowski D., Robinson B., Gandhi S., Burdis-Koch L., Tamblyn J., et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007, 83(3):912-919. discussion 919-20.
5. Gibson B., Chalmers E., Bolton-Maggs P., Henderson D., Lynne R. Thrombembolism in childhood: A prospective 2year BPSU study in the United Kingdom. Thromb Haemost 2003, 1(Suppl1):OC422.
6. deVeber G., Chan A., Monagle P., Marzinotto V., Armstrong D., Massicotte P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: A cohort study. Arch Neurol 1998, 55(12):1533-1537.
7. Andrew M., Monagle P., Brooker L. Arterial thromboembolic complications in pediatric patients. Thromboembolic complications during infancy and childhood 2000, 165-200. Decker Inc, Hamilton, B.C.
8. Kettner S.C., Pollak A., Zimpfer M., Seybold T., Prusa A.R., Herkner K., et al. Heparinase-modified thrombelastography in term and preterm neonates. Anesth Analg 2004, 98(6):1650-1652.
9. Dager W.E., White R.H. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann Pharmacother 2004, 38(2):247-250.
10. Fraser C.J., Newall F., Furmedge J., Campbell J., Savoia H., Monagle P.T. Acute idiopathic portal vein thrombosis in a child: A case report and literature review. Thromb Res 2006, 117(3):279-281.
11. Nowak-Gottl U., Heinecke A., von Kries R., Nurnberger W., Munchow N., Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001, 103(3):165-172.
12. Kuhle S., Koloshuk B., Marzinotto V., Bauman M., Massicotte P., Andrew M., et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003, 111(4-5):227-233.
13. Coombs C.J., Richardson P.W., Dowling G.J., Johnstone B.R., Monagle P., Coombs C.J., et al. Brachial artery thrombosis in infants: An algorithm for limb salvage. Plast Reconstr Surg 2006, 117(5):1481-1488.
14. Newall F., Johnston L., Ignjatovic V., Summerhayes R., Monagle P. Age-related plasma reference ranges for two heparin binding proteins - vitronectin and platelet factor 4. Int J Lab Hematol 2009, 31(6):683-687.
15. Newall F., Savoia H., Campbell J., Monagle P. Anticoagulation clinics for children achieve improved warfarin management. Thromb Res 2004, 114(1):5-9.
16. Newall F., Johnston L., Monagle P. A survey of pediatric cardiology nurses' understanding of warfarin therapy. Pediatr Cardiol 2006, 27(2):204-208.
17. Massicotte P., Leaker M., Marzinotto V., Adams M., Freedom R., Williams W., et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998, 80(4):570-574.
18. Monagle P., Michelson A.D., Bovill E., Andrew M. Antithrombotic therapy in children. Chest 2001, 119(1 Suppl):344S-370S.
19. Streif W., Andrew M., Marzinotto V., Massicotte P., Chan A.K., Julian J.A., et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999, 94(9):3007-3014.
20. Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: The REVIVE trial. Thromb Res 2003, 109(2-3):85-92.
21. Newall F., Campbell J., Savoia H., Barnes C., Monagle P. Incidence of major bleeding in a large paediatric cohort of patients requiring warfarin therapy. J Thromb Haemost 2005, 3(Suppl 1):OR357.
22. Ries M., Klinge J., Rauch R. Erfahrungen mit der antikoagulatientherapie bei 10 patienten an der Univ Kinderklinik Erlangen, in Thrombosen im Kindersalter 1992, Editiones Roche, Basel. A.H. Sutor (Ed.).
23. Taybi H., Capitanio M.A. Tracheobronchial calcification: An observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology 1990, 176(3):728-730.
24. Barnes C., Newall F., Ignjatovic V., Wong P., Cameron F., Jones G., et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005, 57(4):578-581.
25. Massicotte P., Julian J., Webber C. Osteoporosis: A potential complication of long term warfarin therapy. Thromb Haemost 1999, Supply:1333a.
26. Marzinotto V., Monagle P., Chan A., Adams M., Massicotte P., Leaker M., et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000, 21(4):347-352.
27. Massicotte P., Marzinotto V., Vegh P., Adams M., Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr 1995, 127(3):389-394.
28. Newall F., Bauman M. Point-of-care antithrombotic monitoring in children. Thromb Res 2006, 118(1):113-121.
29. Nowatzke W.L., Landt M., Smith C., Wilhite T., Canter C., Luchtman-Jones L. Whole blood international normalization ratio measurements in children using near-patient monitors. J Pediatr Hematol Oncol 2003, 25(1):33-37.
30. Greenway A., Ignjatovic V., Summerhayes R., Newall F., Burgess J., DeRosa L., et al. Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95). Thromb Haemost 2009, 102(1):159-165.
31. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991, 324(26):1865-1875.
32. Monagle P., Barnes C., Ignjatovic V., Furmedge J., Newall F., Chan A., et al. Developmental haemostasis impact for clinical haemostasis laboratories. Thromb Haemost 2006, 95(2):362-372.
33. Ignjatovic V., Summerhayes R., Gan A., Than J., Chan A., Cochrane A., et al. Monitoring unfractionated heparin (UFH) therapy: Which anti factor Xa assay is appropriate?. Thromb Res 2006, 120(3):347-351.
34. Ignjatovic V., Summerhayes R., Than J., Gan A., Monagle P. Therapeutic range for unfractionated heparin therapy: Age-related differences in response in children. J Thromb Haemost 2006, 4(10):2280-2282.
35. Ignjatovic V., Straka E., Summerhayes R., Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost 2010, 8(6):1290-1294.
36. Newall F., Ignjatovic V., Johnston L., Summerhayes R., Lane G., Cranswick N., et al. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 2010, 103(5).
37. Newall F., Cranswick N., Ignjatovic V., Johnston L., Lane G., Summerhayes R., et al. Unfractionated heparin pharmacokinetic profile in children, in XXII Congress, International Society on Thrombosis and Haemostasis 2009, Boston.
38. Andrew M., Marzinotto V., Massicotte P., Blanchette V., Ginsberg J., Brill-Edwards P., et al. Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 1994, 35(1):78-83.
39. Kuhle S., Eulmesekian P., Kavanagh B., Massicotte P., Vegh P., Mitchell L.G. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: A prospective cohort study. Haematologica 2007, 92(2):244-247.
40. Avioli L.V. Heparin-induced osteopenia: An appraisal. Adv Exp Med Biol 1975, 52:375-387.
41. Murphy M.S., John P.R., Mayer A.D., Buckels J.A., Kelly D.A. Heparin therapy and bone fractures. Lancet 1992, 340(8827):1098.
42. Schuster J., Meier-Ruge W., Egli F. Pathology of osteopathy following heparin therapy. Dtsch Med Wochenschr 1969, 94(45):2334-2338.
43. Sackler J.P., Liu L. Heparin-induced osteoporosis. Br J Radiol 1973, 46(547):548-550.
44. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia. Chest 2008, 133(6 suppl):340S-380S.
45. Klement D., Rammos S., v Kries R., Kirschke W., Kniemeyer H.W., Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996, 155(1):11-14.
46. Magnani H.N. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993, 70(4):554-561.
47. Murdoch I.A., Beattie R.M., Silver D.M. Heparin-induced thrombocytopenia in children. Acta Paediatr 1993, 82(5):495-497.
48. Potter C., Gill J.C., Scott J.P., McFarland J.G. Heparin-induced thrombocytopenia in a child. J Pediatr 1992, 121(1):135-138.
49. Severin T., Sutor A.H. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001, 27(3):293-299.
50. Boshkov L., Ibsen L., Kirby A., Ungerleider R.I.S. Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: A likely under-recognized complication with significant morbidity and mortality: Report of 4 sequential cases. J Thromb Haemost 2003, 1(Suppl1):1494a.
51. Etches W., Stang L., Conradi A. Incidence of heparin-induced thrombocytopenia in a pediatric intensive care population. Blood 2003, 102(Suppl):536a.
52. Klenner A.F., Fusch C., Rakow A, Kadow I., Beyersdorff E., Eichler P., et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: A placebo-controlled trial. J Pediatr 2003, 143(6):741-745.
53. Newall F., Barnes C., Ignjatovic V., Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003, 39(4):289-292.
54. Schmugge M., Risch L., Huber A.R., Benn A., Fischer J.E. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002, 109(1):E10.
55. Spadone D. Heparin induced thrombocytopenia in the newborn. J Vasc Surg 1996, 15:306-312.
56. Lo G.K., Sigouin C.S., Warkentin T.E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007, 82(12):1037-1043.
57. Klenner A., G.A. Heparin-induced thrombocytopenia in children. Heparin-induced thrombocytopenia 2004, 553-571. Marcel Dekker Inc, New York, NY. 3rd ed. T. Warkentin, A. Greinacher (Eds.).
58. Risch L., Fischer J.E., Herklotz R., Huber A.R. Heparin-induced thrombocytopenia in paediatrics: Clinical characteristics, therapy and outcomes. Intensive Care Med 2004, 30(8):1615-1624.
59. Saxon B.R., Black M.D., Edgell D., Noel D., Leaker M.T. Pediatric heparin-induced thrombocytopenia: Management with Danaparoid (orgaran). Ann Thorac Surg 1999, 68(3):1076-1078.
60. Severin T., Zieger B., Sutor A.H. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002, 28(5):447-454.
61. Chan V.H., Monagle P., Massicotte P., Chan A.K. Novel paediatric anticoagulants: a review of the current literature. Blood Coagul Fibrinolysis 2010, 21(2):144-151.
62. Galant S.P. Accidental heparinization of a newborn infant. Am J Dis Child 1967, 114(3):313-319.
63. Glueck H.I., Light I.J., Flessa H., Sutherland J.M. Inadvertent sodium heparin administration to a newborn infant. JAMA 1965, 191:1031-1032.
64. Moncino M.D., Kurtzberg J. Accidental heparinization in the newborn: A case report and brief review of the literature. J Perinatol 1990, 10(4):399-402.
65. Pachman D.J. Accidental heparin poisoning in an infant. Am J Dis Child 1965, 110:210-212.
66. Pegelow C.H., Powars D. Inadvertent heperanization as a complication of intensive care. Clin Res 1975, 23:161A.
67. Schreiner R.L., Wynn R.J., McNulty C. Accidental heparin toxicity in the newborn intensive care unit. J Pediatr 1978, 92(1):115-116.
68. US Food Drug Administration FDA drug safety communication: Update: Follow up to the public health alert about changes to the heparin sodium USP monograph. Postmarket drug safety information for patients and providers 2010, 15/04/2010 [cited 22/04/2010]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/ucm207506.htm.
69. Hirsh J., Warkentin T.E., Raschke R., Granger C., Ohman E.M., Dalen J.E. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114(5 Suppl):489S-510S.
70. Michelson A.D., Bovill E., Monagle P., Andrew M. Antithrombotic therapy in children. Chest 1998, 114(5 Suppl):748S-769S.
71. Bontadelli J., Moeller A., Schmugge M., Kretschmar O., Bauersfeld U., Schraner T., et al. Use of enoxaparin in the treatment of catheter-related arterial thrombosis in infants with congenital heart disease. Cardiol Young 2006, 16(Supplement 2):27.
72. Burak C.R., Bowen M.D., Barron T.F. The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatr Neurol 2003, 29(4):295-298.
73. Dix D., Andrew M., Marzinotto V., Charpentier K., Bridge S., Monagle P., et al. The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatr 2000, 136(4):439-445.
74. Dix D., Charpentier K., Sparling C., et al. Determining of trough anti-factor Xa levels in pediatric patients on low molecular weight heparin (LMWH). J Pediatr Hematol Oncol 1998, 20(4):398.
75. Dunaway K.K., Gal P., Ransom J.L. Use of enoxaparin in a preterm infant. Ann Pharmacother 2000, 34(12):1410-1413.
76. Elhasid R., Lanir N., Sharon R., Weyl Ben Arush M., Levin C., Postovsky S., et al. Prophylactic therapy with enoxaparin during l-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001, 12(5):367-370.
77. Revel-Vilk S., Sharathkumar A., Massicotte P., Marzinotto V., Daneman A., Dix D., et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by ultrasound. J Thromb Haemost 2004, 2(1):42-46.
78. Schobess R., During C., Bidlingmaier C., Heinecke A., Merkel N., Nowak-Gottl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: An open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006, 91(12):1701-1704.
79. Streif W., Goebel G., Chan A.K., Massicotte M.P. Use of low molecular mass heparin (enoxaparin) in newborn infants: A prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 2003, 88(5):F365-F370.
80. Kuhle S., Massicotte M.P., Andrew M. A dose-finding study of Tinzaparin in pediatric patients. Blood 2002, 100:279a.
81. Massicotte M.P., Adams M., Leaker M. A normogram to establish therapeutic levels of low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE). Thromb Haemost 1997, Supplement:1-843.
82. Nohe N., Flemmer A., Rumler R., Praun M., Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases. Eur J Pediatr 1999, 158(Suppl 3):S134-S139.
83. Chan A.K., Berry L.R., Monagle P.T., Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost 2002, 87(4):606-613.
84. Ignjatovic V., Summerhayes R., Newall F., Monagle P.T. The in vitro response to low-molecular-weight heparin is not age-dependent in children. Thromb Haemost 2010, 103(4).
85. Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Thromb Res 2003, 109(2-3):101-108.
86. Malowany J.I., Monagle P., Knoppert D.C., Lee D.S., Wu J., McCusker P., et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. Thromb Res 2008, 122(6):826-830.
87. Ignjatovic V., Najid S., Newall F., Summerhayes R., Monagle P. Dosing and monitoring of enoxaparin (LMWH) therapy in children. Br J Haematol 2010, 149(5):734-738.
88. Massicotte P., Adams M., Marzinotto V., Brooker L.A., Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study. J Pediatr 1996, 128(3):313-318.
89. Bradley L., Midgley F., Watson D., Getson P., Scott L. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol 1985, 56(8):533-535.
90. Doyle J.J., Koren G., Cheng M.Y., Blanchette V.S. Anticoagulation with sodium warfarin in children: Effect of a loading regimen. J Pediatr 1988, 113(6):1095-1097.
91. Andrew M., David M., Adams M., Ali K., Anderson R., Barnard D., et al. Venous thrombotic complications (VTE) in children; first analysis of the Canadian registry of VTE. Blood 1994, 83(5):1251-1257.
92. Tait R.C., Ladusans E.J., El-Metaal M., Patel R.G., Will A.M. Oral anticoagulation in paediatric patients: Dose requirements and complications. Arch Dis Child 1996, 74(3):228-231.
93. Cheung Y.F., Leung M.P. Low dose oral anticoagulation therapy in Chinese children with congenital heart disease. J Paediatr Child Health 1998, 34(6):563-567.
94. Soper J., Chan G.T., Skinner J.R., Spinetto H.D., Gentles T.L. Management of oral anticoagulation in a population of children with cardiac disease using a computerised system to support decision-making. Cardiol Young 2006, 16(3):256-260.
95. Bonduel M., Sciuccati G., Hepner M., Torres A.F., Pieroni G., Frontroth J.P., et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost 2003, 1(8):1740-1743.
96. Woods A., Vargas J., Berri G., Kreutzer G., Meschengieser S., Lazzari M.A. Antithrombotic therapy in children and adolescents. Thromb Res 1986, 42(3):289-301.
97. Ekert H., Seshadri R. Heparin treatment in childhood and its effect on monitoring tests. Aust Paediatr J 1973, 9(5):269-275.
98. Freed M.D., Keane J.F., Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation 1974, 50(3):565-569.
99. McDonald M., Hathaway W. Anticoagulation therapy by continuous heparinization in newborn and older infants. J Pediatr 1982, 101(3).
100. von Kries R., Stannigel H., Gobel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. Eur J Pediatr 1985, 144(2):191-194.
101. Netz H., Madu B., Rohner G. Heparinization during percutaneous cardiac catheterization in children. Pediatr Cardiol 1987, 8(3):167-168.
102. Grady R.M., Eisenberg P.R., Bridges N.D. Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol 1995, 25(3):725-729.
103. Saxena A., Gupta R., Kumar R.K., Kothari S.S., Wasir H.S. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Catheter Cardiovasc Diagn 1997, 41(4):400-403.
104. Codispoti M., Ludlam C.A., Simpson D., Mankad P.S. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 2001, 71(3):922-927. discussion 927-8.
105. Nankervis C.A., Preston T.J., Dysart K.C., Wilkinson W.D., Chicoine L.G., Welty S.E., et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007, 53(1):111-114.
106. Guzzetta N.A., Bajaj T., Fazlollah T., Szlam.F., Wilson E., Kaiser A., et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008, 106(2):419-425. table of contents.
107. Ignjatovic V., Summerhayes R., Gan A., Than J., Chan A., Cochrane A., et al. Monitoring unfractionated heparin (UFH) therapy: Which anti-factor Xa assay is appropriate?. Thromb Res 2007, 120(3):347-351.
108. Newall F., Ignjatovic V., Summerhayes R., Gan A., Butt W., Johnston L., et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res 2009, 123(5):710-714.
109. Hofmann S., Knoefler R., Lorenz N., Siegert G., Wendisch J., Mueller D., et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 2001, 103(5):345-353.
110. Strater R., Kurnik K., Heller C., Schobess R., Luigs P., Nowak-Gottl U. Aspirin versus low-dose low-molecular-weight heparin: Antithrombotic therapy in pediatric ischemic stroke patients: A prospective follow-up study. Stroke 2001, 32(11):2554-2558.
111. Massicotte P., Julian J.A., Marzinotto V., Gent M., Shields K., Chan A.K., et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003, 109(2-3):93-99.
112. Kuhle S., Massicotte P., Dinyari M., Vegh P., Mitchell D., Marzinotto V., et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005, 94(6):1164-1171.